Alliance Global Partners Comments on Cresco Labs Q4 Earnings

Cresco Labs Inc. (OTCMKTS:CRLBF - Free Report) - Research analysts at Alliance Global Partners issued their Q4 2024 earnings estimates for shares of Cresco Labs in a note issued to investors on Wednesday, October 30th. Alliance Global Partners analyst A. Grey anticipates that the company will post earnings of ($0.01) per share for the quarter. The consensus estimate for Cresco Labs' current full-year earnings is ($0.15) per share.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.15). Cresco Labs had a negative net margin of 23.07% and a negative return on equity of 17.03%. The company had revenue of $184.36 million during the quarter, compared to analyst estimates of $184.26 million.

Other research analysts have also issued research reports about the company. Needham & Company LLC reissued a "hold" rating on shares of Cresco Labs in a report on Monday, August 12th. Roth Capital raised shares of Cresco Labs from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 9th. Finally, Ventum Cap Mkts raised shares of Cresco Labs to a "strong-buy" rating in a report on Friday, August 9th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $2.50.

Cresco Labs Stock Performance

Shares of Cresco Labs stock traded up $0.05 during trading on Friday, reaching $1.52. The company's stock had a trading volume of 321,428 shares, compared to its average volume of 725,183. The firm has a market cap of $739.53 million, a PE ratio of -2.86 and a beta of 1.86. The company has a 50-day moving average price of $1.63 and a two-hundred day moving average price of $1.75. The company has a current ratio of 2.00, a quick ratio of 1.30 and a debt-to-equity ratio of 1.76. Cresco Labs has a fifty-two week low of $1.11 and a fifty-two week high of $2.65.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.